Active Ingredient(s): Fosaprepitant Dimeglumine
FDA Approved: * September 5, 2019
Pharm Company: * TEVA PHARMS USA INC
Category: Nausea & Vomiting

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the U.S. Food and Drug Administration (FDA) on January 25, 2008,[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Related Brands

Drugs with the same active ingredients